FKBP9 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to the FK506 binding protein (FKBP12), but it can also bind to other FKBP proteins, potentially including FKBP9. This complex then inhibits the mTOR pathway, which is critical for protein synthesis and cellular proliferation. Inhibition of mTOR could reduce the functional activity of FKBP9 by decreasing the processes that depend on mTOR signaling. | ||||||
Ascomycin | 104987-12-4 | sc-207303B sc-207303 sc-207303A | 1 mg 5 mg 25 mg | $36.00 $173.00 $316.00 | ||
Ascomycin is a macrolide immunosuppressant that binds to FKBP proteins, and this could include FKBP9. The FKBP-ascomycin complex inhibits calcineurin, leading to inhibition of T-cell activation. If FKBP9 is involved in similar immune signaling pathways, its activity could be indirectly inhibited by the suppression of calcineurin signaling. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
Everolimus is another derivative of sirolimus and has a similar mechanism of action, binding to FKBP proteins and inhibiting mTOR. This inhibition could also lead to decreased FKBP9 activity if FKBP9 is involved in mTOR-related pathways. | ||||||
Zotarolimus | 221877-54-9 | sc-213188 | 1 mg | $240.00 | ||
Zotarolimus is a derivative of rapamycin and shares a similar mechanism. By inhibiting mTOR via FKBP protein binding, it could indirectly affect the activity of FKBP9 if FKBP9 functions are related to the mTOR signaling pathway. | ||||||
Pimecrolimus | 137071-32-0 | sc-208172 | 1 mg | $140.00 | 2 | |
Pimecrolimus binds to FKBP proteins and inhibits calcineurin. While its primary target is FKBP12, FKBP9 activity could be indirectly inhibited if it is part of the calcineurin signaling pathway. | ||||||
PIK-75, hydrochloride | 372196-77-5 | sc-296089 sc-296089A | 1 mg 5 mg | $28.00 $122.00 | ||
PIK-75 is an inhibitor of phosphoinositide 3-kinase (PI3K), which acts upstream of mTOR. By inhibiting PI3K, PIK-75 could reduce mTOR activity, potentially leading to an indirect decrease in FKBP9 activity if FKBP9 is linked to the PI3K/mTOR signaling axis. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another PI3K inhibitor, which could indirectly inhibit FKBP9 by downregulating the PI3K/mTOR pathway. If FKBP9 is involved in this pathway, the inhibition of PI3K would lead to a decrease in FKBP9 functional activity. | ||||||
WYE-354 | 1062169-56-5 | sc-364652 sc-364652A | 10 mg 50 mg | $286.00 $1200.00 | ||
WYE-354 is an mTOR inhibitor that could lead to decreased FKBP9 activity by dampening the mTOR signaling pathway. If FKBP9 is functionally active in this pathway, its activity would be indirectly inhibited by this compound. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $240.00 | 7 | |
Torin 1 is a potent inhibitor of mTOR that could indirectly decrease FKBP9 activity by inhibiting the mTOR pathway. If FKBP9 participates in mTOR-dependent processes, its activity would be reduced by this compound. | ||||||